BRIEF: XTL acquires 31 percent stake in Proteologics from Teva 

BRIEF: XTL acquires 31 percent stake in Proteologics from Teva

Nov 22, 2012 (Menafn - Globes - McClatchy-Tribune Information Services via COMTEX) --Biopharmaceutical company Proteologics Ltd.'s (tase:PRTL) share price has risen sharply in heavy trading on the Tel Aviv Stock Exchange (TASE) after reporting that XTL Biopharmaceuticals Ltd. XTLB.Y; TASE:XTL) acquired 4,620,356 of its shares from Teva Pharmaceutical Industries Ltd. TEVA(tase:TEVA). This represents a 31.3 percent stake in Proteologics at a 20 percent premium on today's opening price.

Before the deal Teva was the controlling shareholder in Proteologics.

XTL probably conceived the idea of acquiring the stake in Proteologics after the company's chairman Dr. Aharon Schwartz recently proposed a merger with Biocancell Therapeutics Ltd. (tase:BICL). This proposal possibly brought Proteologics to XTL's attention.

Proteologics is a drug development company focuses primarily on discovering inhibitors for specific E3 ubiquitin ligases.

Proteologics share price was up 21.85 percent in afternoon trading on the TASE to NIS 1.40 after rising 4.5 percent yesterday.

___ (c)2012 the Globes (Tel Aviv, Israel) Visit the Globes (Tel Aviv, Israel)
at www.globes.co.il/serveen/globes/nodeview.asp?fid=942 Distributed by MCT
Information Services

Copyright (C) 2012, Globes, Tel Aviv, Israel